Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan

Inclusion Criteria: * Body mass index (BMI): ≥ 18 and ≤ 32 kg/m² at the first screening visit * Absence of clinically relevant abnormal findings in the pre-treatment endometrial biopsy * Pre-treatment cycle assessed as ovulatory and not longer than 44 days Exclusion Criteria: * Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal * Known or suspected liver disorders * Amenorrhea for more than 3 months within the last 6 months before the first screening examination * Clinically relevant findings (e.g. blood pressure, electrocardiogram \[ECG\], physical and gynecological examination, laboratory examination) * Positive urine pregnancy test * Regular use of medicines